Neumora Therapeutics (NMRA) Liabilities and Shareholders Equity (2022 - 2026)

Neumora Therapeutics' Liabilities and Shareholders Equity history runs 5 years deep, the most recent figure standing at $153.9 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 40.07% year-over-year to $153.9 million; the TTM figure through Mar 2026 stood at $746.6 million (down 43.9% YoY), while the FY2025 annual figure was $191.0 million, down 39.73% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $153.9 million, down from $191.0 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $544.7 million in Q3 2023, with the low at $153.9 million in Q1 2026.
• The 5-year median for Liabilities and Shareholders Equity is $334.8 million (2024), against an average of $332.9 million.
• The sharpest annual moves came in 2023 and 2025: Liabilities and Shareholders Equity advanced 16.41% in 2023, then sank 49.56% in 2025.
• Neumora Therapeutics' Liabilities and Shareholders Equity stood at $426.2 million in 2022, then climbed by 16.41% to $496.2 million in 2023, then sank by 36.12% to $317.0 million in 2024, then sank by 39.73% to $191.0 million in 2025, then decreased by 19.46% to $153.9 million in 2026.
• Business Quant data shows NMRA's Liabilities and Shareholders Equity at $153.9 million in Q1 2026, $191.0 million in Q4 2025, and $177.8 million in Q3 2025.